---
title: "Iovance Biotherapeutics, Inc. (IOVA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IOVA.US.md"
symbol: "IOVA.US"
name: "Iovance Biotherapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T16:07:27.991Z"
locales:
  - [en](https://longbridge.com/en/quote/IOVA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IOVA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IOVA.US.md)
---

# Iovance Biotherapeutics, Inc. (IOVA.US)

## Company Overview

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.iovance.com](https://www.iovance.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.46)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 100 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 34.29% |  |
| Net Profit YoY | 5.73% |  |
| P/B Ratio | 2.14 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1544898290.16 |  |
| Revenue | 285608000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -47.51% | E |
| Profit Margin | -123.90% | E |
| Gross Margin | 40.50% | B |
| Revenue YoY | 34.29% | A |
| Net Profit YoY | 5.73% | C |
| Total Assets YoY | -4.25% | D |
| Net Assets YoY | -6.01% | D |
| Cash Flow Margin | 76.52% | C |
| OCF YoY | 34.29% | A |
| Turnover | 0.30 | D |
| Gearing Ratio | 22.03% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Iovance Biotherapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "34.29%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "5.73%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.14",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1544898290.16",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "285608000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-47.51%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-123.90%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "40.50%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "34.29%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "5.73%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-4.25%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-6.01%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "76.52%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "34.29%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.30",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "22.03%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.37 | 364/386 | - | - | - |
| PB | 2.14 | 200/386 | 2.02 | 1.31 | 1.04 |
| PS (TTM) | 5.41 | 115/386 | 5.32 | 3.81 | 3.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 60% |
| Overweight | 2 | 20% |
| Hold | 2 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.56 |
| Highest Target | 16.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IOVA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IOVA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IOVA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IOVA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**